Pazopanib (Votrient) for the treatment of locally advanced and/or metastatic renal cell carcinoma
Hintringer K
Record ID 32011000467
English
Authors' recommendations:
Overall, the efficacy and safety profile of pazopanib is considered positive. Though, there are still a couple of questions unanswered – e.g. mature OS data of the ongoing pivotal phase III trial and direct comparative data of pazopanib and other approved agents and the efficacy and safety of 2nd-line pazopanib in patients initially treated with other systemic therapy than cytokines. Based on the current evidence on the available targeted agents for the firstline treatment of locally advanced and/or metastatic RCC, it is not possible to accurately define superiority in terms of clinical efficacy for one of the agents over another.
Details
Project Status:
Completed
URL for project:
http://eprints.hta.lbg.ac.at/902
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Kidney Neoplasms
- Pyrimidines
- Sulfonamides
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.